/biz/ - Business & Finance

>>PICK UP 4/16 $2.50CALLS. THEY ARE CHEAP

Poster on Celsion Corporation's Phase I/II OVATION 2 Study to be Presented at the Society of Gynecologic Oncology Virtual Annual Meeting on Women's Cancer
LAWRENCEVILLE, N.J., March 02, 2021 (GLOBE NEWSWIRE) --Celsion Corporation(NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that a poster on the Company's Phase I/II OVATION 2 Study with GEN-1 in advanced ovarian cancer has been accepted for presentation at the Virtual Annual Meeting on Women's Cancer, sponsored by the Society of Gynecologic Oncology.

The conference is being held March 19-25, 2021. The OVATION 2 Study design is being presented as a poster entitled "A Phase I/II Study Evaluating Intraperitoneal GEN-1 in Combination with Neoadjuvant Chemotherapy in Patients with Newly Diagnosed Advanced Epithelial Ovarian Cancer (EOC)" in the "Trials in Progress" poster session from March 19 to 25 (8 pm to 11 pm each day). GEN-1 is Celsion's DNA-mediated interleukin-12 (IL-12) immunotherapy designed using TheraPlas, its proprietary, synthetic, non-viral nanoparticle delivery system platform.